AG真人官方

STOCK TITAN

Viemed Healthcare Inc SEC Filings

VMD NASDAQ

Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Looking for Viemed Healthcare鈥檚 shifting Medicare reimbursement disclosures or payor-mix trends before the next earnings call? Start here. Our SEC filings hub gathers every VMD document the moment it hits EDGAR, so you can move straight to the schedules that explain how home-ventilation revenue, equipment rentals, and neuromuscular therapy services impact cash flow and compliance.

Use Stock Titan鈥檚 AI to translate dense language into clear takeaways: Viemed Healthcare quarterly earnings report 10-Q filing summaries spotlight segment margins; Viemed Healthcare annual report 10-K simplified highlights list CMS rule changes and readmission-rate data; and Viemed Healthcare 8-K material events explained alerts you to sudden reimbursement updates or payer audits. AG真人官方-time monitors push Viemed Healthcare Form 4 insider transactions real-time so you can see executive stock moves alongside Viemed Healthcare executive stock transactions Form 4 commentary. Need governance data? The Viemed Healthcare proxy statement executive compensation section parses bonus triggers tied to patient-outcome metrics.

Whether you鈥檙e screening for policy risk, modeling DME inventory turns, or tracking Viemed Healthcare insider trading Form 4 transactions, our platform answers the questions professionals actually ask: 鈥渦nderstanding Viemed Healthcare SEC documents with AI,鈥� 鈥淰iemed Healthcare earnings report filing analysis,鈥� and 鈥淰iemed Healthcare SEC filings explained simply.鈥� Skip the 300-page PDFs鈥擜I-powered summaries, keyword search, and downloadable tables let you compare trends, flag anomalies, and act with confidence.

Rhea-AI Summary

Viemed Healthcare, Inc. (VMD) filed an 8-K to announce the closing of its acquisition of Lehan鈥檚 Medical Equipment, a privately held home medical equipment provider based in DeKalb, Illinois. The transaction consists of a $26 million base purchase price, subject to customary adjustments, plus an estimated $2.2 million contingent consideration.

The company stated that it will update its full-year 2025 guidance to reflect Lehan鈥檚 expected contribution when it reports Q2 2025 earnings (period ended June 30, 2025). No immediate changes to guidance or pro-forma financials were included in this filing; the related press release is furnished as Exhibit 99.1 and deemed 鈥渇urnished,鈥� not 鈥渇iled,鈥� under the Exchange Act.

For investors, the filing signals completion of a strategic bolt-on acquisition that expands VMD鈥檚 geographic reach into Illinois and broadens its home medical equipment offerings. The cash outlay and contingent payments may affect near-term liquidity, while future revenue impact will be clarified with the forthcoming guidance update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Forager Capital Management, LLC, together with its affiliated investment vehicle Forager Fund, L.P. and principals Edward Kissel and Robert MacArthur, has filed a Schedule 13G disclosing ownership of 2,186,472 shares of Viemed Healthcare, Inc. (VMD) common stock.

The position represents 5.5 % of Viemed鈥檚 39.52 million shares outstanding as reported in the company鈥檚 10-Q for the quarter ended 31 Mar 2025. Because the stake exceeds the 5 % threshold, the group is required to disclose its holdings under Section 13(d) of the Exchange Act. The filing is made pursuant to Rule 13d-1(b), indicating that the investors view the holding as passive rather than activist.

Voting and dispositive powers are split as follows: (i) Forager Fund and Forager Capital Management each hold sole voting and dispositive power over the full 2.19 million shares; (ii) Messrs. Kissel and MacArthur share voting and dispositive power over the same shares through their control of the fund and general partner. No other party is reported to have an economic interest in the shares.

The event date is 24 Jun 2025, with the joint filing signed on 1 Jul 2025. The certification clause confirms that the securities were not acquired with the intent to change or influence control of the issuer.

  • The disclosure introduces a new institutional shareholder representing a sizeable block for a small-cap healthcare company.
  • Filing type (Schedule 13G vs. 13D) suggests a passive, long-only orientation, reducing immediate governance or strategic pressure on Viemed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Palo Alto Networks, Inc. (PANW) 鈥� Form 144 filing dated July 1, 2025 discloses a proposed secondary sale of 300,000 common shares by family-related trusts through J.P. Morgan Securities LLC. The shares carry an estimated aggregate market value of $61.392 million based on recent prices and represent approximately 0.05 % of the company鈥檚 666.8 million shares outstanding, implying limited ownership dilution because no new shares are being issued.

The trusts involved (Hawk Family Trust and multiple Cliff Family Trust sub-accounts) have been active sellers. Over the previous three months they completed eight open-market transactions totaling 鈮�959,796 shares and $145.6 million in gross proceeds, with sales executed on 11-Apr-2025, 1-May-2025 and 2-Jun-2025. The forthcoming 300 k-share block would lift the rolling four-month total to roughly 1.26 million shares.

All sales are made pursuant to Rule 144, which permits resale of restricted or control securities subject to volume, manner-of-sale and notice requirements. The seller certifies that no undisclosed material adverse information is known and, if applicable, that any Rule 10b5-1 trading plan was adopted on the date indicated.

Investment takeaways:

  • The filing signals continued insider-related supply but on a scale unlikely to materially affect PANW鈥檚 float or trading liquidity.
  • Because these are secondary sales, no cash flows to the company; proceeds accrue solely to the trusts.
  • Investors may nevertheless monitor insider sentiment, especially given the nine-month cadence of sizable disposals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Ford Motor Company (symbol: F) has filed a Form 144 indicating the proposed sale of 30,000 common shares under Rule 144 of the Securities Act of 1933. The shares will be sold through UBS Financial Services, Inc., 11 Madison Ave., New York, NY 10010, with an aggregate market value of $330,000. The approximate sale date disclosed is 07/01/2025, and the shares are to be listed on the NYSE.

The filing shows that the seller originally acquired the shares via three restricted-stock unit (RSU) vesting events on 03/02/2021 (5,424 shares), 03/04/2022 (13,949 shares) and 03/04/2024 (10,627 shares), matching the total of 30,000 shares to be sold. Ford鈥檚 total shares outstanding, as referenced in the filing, are 3,905,696,769; therefore, the proposed sale represents roughly 0.0008 % of shares outstanding鈥攁n immaterial fraction from a market-capitalization standpoint.

No prior sales were reported during the last three months, and no remarks or 10b5-1 plan adoption dates were disclosed. The filer has affirmed that he or she is not in possession of undisclosed material adverse information.

Investment take-away: While the notice signals insider intent to liquidate equity worth $330,000, the volume is negligible relative to Ford鈥檚 float and should not, by itself, influence the valuation or liquidity of Ford shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

On June 30, 2025, The Bancorp, Inc. (Nasdaq: TBBK) filed an amended Form 8-K to update investors on the disposition of a non-performing real-estate bridge-lending asset classified as Other AG真人官方 Estate Owned (OREO). The apartment-complex asset carries a balance of $42.9 million as of June 30, 2025.

The company terminated the sale agreement on June 24, 2025 and demanded that the escrow agent release $3.0 million in earnest-money deposits to the company. Two days later, the buyer objected to the release without citing contractual grounds. Management asserts its entitlement to the funds and "intends to pursue" their release.

Beyond the OREO balance and deposit amount, no incremental financial or earnings data were provided, nor was a new timeline for monetizing the asset disclosed. The remainder of the filing consists of customary forward-looking-statement language and signature blocks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Viemed Healthcare (VMD)?

The current stock price of Viemed Healthcare (VMD) is $7.08 as of July 2, 2025.

What is the market cap of Viemed Healthcare (VMD)?

The market cap of Viemed Healthcare (VMD) is approximately 275.9M.

What core services does Viemed Healthcare Inc offer?

Viemed Healthcare Inc provides comprehensive respiratory disease management, home therapy solutions, oxygen therapy, sleep apnea treatment, in-home sleep testing, and specialized neuromuscular care.

How does the company support patients transitioning from hospital to home care?

The company integrates a targeted home treatment model with a well-coordinated referral network involving hospitals, ACOs, and skilled nursing facilities, ensuring a seamless transition for patients.

What role does technology play in Viemed's operations?

Viemed leverages advanced medical equipment and the latest technology to deliver efficient and effective home-based therapies, enhancing patient outcomes and operational efficiency.

How does Viemed Healthcare integrate with other healthcare providers?

Viemed works closely with hospitals and various referral partners to streamline the administrative process of transitioning patients from acute care to home-based care, ensuring continuity in treatment.

What are the primary revenue streams for the company?

The company primarily generates revenue through the rental, sale, and supply of medical equipment, along with providing specialized home therapy services and healthcare staffing support.

How does the company achieve improved patient outcomes?

Through its specialized respiratory care, educational initiatives, and a structured home therapy model, Viemed consistently achieves industry-recognized outcomes such as reduced hospital readmission rates and high patient satisfaction.

How is Viemed differentiated from other providers in the healthcare sector?

Viemed distinguishes itself with a focused approach on respiratory disease management, its seamless integration of advanced technology in home therapy, and strong collaborations with diverse healthcare partners.

Can you elaborate on the company's approach to managing respiratory diseases?

The company combines clinical expertise with patient education and state-of-the-art technology to deliver personalized respiratory care, ensuring that patients receive targeted treatment and effective follow-up support at home.
Viemed Healthcare Inc

NASDAQ:VMD

VMD Rankings

VMD Stock Data

275.88M
34.40M
13%
64.98%
0.74%
Medical Devices
Services-misc Health & Allied Services, Nec
United States
LAFAYETTE